Aimei Health Technology Co., Ltd. (NASDAQ:AFJK) Short Interest Up 94.6% in June

Aimei Health Technology Co., Ltd. (NASDAQ:AFJK) was the recipient of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,249 shares, an increase of 94.6% from the June 15th total of 2,184 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 11,212 shares, the short-interest ratio is currently 0.4 days.

Aimei Health Technology Stock Up 0.9%

NASDAQ:AFJK opened at $11.80 on Thursday. The firm has a market capitalization of $37.36 million, a P/E ratio of 73.75 and a beta of 0.55. The company has a fifty day moving average of $33.62 and a 200 day moving average of $40.27. Aimei Health Technology has a 52 week low of $6.75 and a 52 week high of $130.37.

Aimei Health Technology (NASDAQ:AFJK) last released its quarterly earnings data on Tuesday, June 16th. The company reported $0.01 earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AFJK. Clear Street Group Inc. raised its position in Aimei Health Technology by 36.5% during the 4th quarter. Clear Street Group Inc. now owns 83,337 shares of the company’s stock valued at $5,334,000 after purchasing an additional 22,294 shares during the last quarter. Jane Street Group LLC purchased a new stake in Aimei Health Technology in the 4th quarter worth approximately $302,000. Geode Capital Management LLC bought a new stake in shares of Aimei Health Technology in the 4th quarter worth approximately $413,000. Quarry LP grew its position in shares of Aimei Health Technology by 6.4% in the 3rd quarter. Quarry LP now owns 167,081 shares of the company’s stock worth $1,891,000 after buying an additional 10,000 shares during the last quarter. Finally, Dakota Wealth Management purchased a new position in shares of Aimei Health Technology during the fourth quarter valued at approximately $406,000. Hedge funds and other institutional investors own 45.58% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Aimei Health Technology in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Aimei Health Technology presently has a consensus rating of “Sell”.

Aimei Health Technology Company Profile

Aimei Health Technology Co, Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors. Aimei Health Technology Co, Ltd was incorporated in 2023 and is based in New York, New York.